Paired Stimulation Plasticity for Motor Recovery in Humans With and Without Spinal Cord Injury
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Monica Perez
- Número de teléfono: 312-238-2886
- Correo electrónico: mperez04@sralab.org
Ubicaciones de estudio
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Reclutamiento
- Shirley Ryan Abilitylab
-
Contacto:
- Monica Perez
- Número de teléfono: 312-238-2886
- Correo electrónico: mperez04@sralab.org
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Male and females between 19-85 years;
- Chronic SCI (≥ 1 years post-injury);
- T10 or above - American Spinal Injury Association (AIS) Grade C, or D;
- Ability to perform a small voluntary ankle dorsiflexion, knee extension, and ankle plantarflexion (as detected by presence of voluntary EMG activity in the rectus femoris, tibialis anterior, and soleus muscles) with at least one leg;
- Ability to tolerate standing position;
- Ability to initiate at least one step without the assistance of a therapist;
- If ambulatory, ability to walk at a minimum speed of 0.1 m/s on a treadmill. Inclusion criteria for controls:
- Male and females (19-85 years);
- Able to perform dorsiflexion;
- Able to walk.
Exclusion Criteria:
- Uncontrolled medical problems including pulmonary, cardiovascular, or orthopedic disease;
- Any debilitating disease before the SCI that caused exercise intolerance;
- Premorbid, ongoing major depression or psychosis, altered cognitive status;
- History of head injury or stroke;
- Pacemaker;
- Metal plate in skull;
- History of seizures;
- Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold, such as antipsychotic drugs (chlorpromazine, clozapine) or tricyclic antidepressants;
- Pregnancy;
- Ongoing cord compression or a syrinx in the spinal cord or spinal cord disease, such as spinal stenosis, spina bifida or herniated cervical disk;
- implanted defibrillators or implanted neurostimulators;
- have large ischaemic scars;
- diagnosed sleep deprivation.
Exclusion criteria for controls:
- Same as for subjects with SCI.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
control saludable
|
transcranial magnetic stimulation and peripheral nerve stimulation are given at almost the same time to target brain-to-spinal cord connections
transcranial magnetic stimulation and peripheral nerve stimulation are given at almost the same time to target brainstem-to-spinal cord connections
the setup will look and feel the same to the participant as the CST PAS or RST PAS.
But one or both of the stimulations is not actually delivered, or it is delivered in a way that does not affect the participant
|
|
spinal cord injury
|
transcranial magnetic stimulation and peripheral nerve stimulation are given at almost the same time to target brain-to-spinal cord connections
transcranial magnetic stimulation and peripheral nerve stimulation are given at almost the same time to target brainstem-to-spinal cord connections
the setup will look and feel the same to the participant as the CST PAS or RST PAS.
But one or both of the stimulations is not actually delivered, or it is delivered in a way that does not affect the participant
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Motor evokoed potential
Periodo de tiempo: Periprocedural
|
Transcranial magnetic stimuli (TMS) will be delivered from a Magstim 200 stimulator (Magstim Company) through a double-cone coil with a monophasic current waveform.
TMS will be delivered to the optimal scalp position for activation of upper or lower limb muscles.
The optimal scalp position will be determined by moving the coil in small steps along the arm/leg muscle representation of the primary motor cortex to find the region where the largest MEP can be evoked with the minimum intensity in the targeted muscles.
The muscles to be activated will be upper limb muscles such as deltoid, biceps, triceps, extensor carpi radialis, flexor carpi radialis and/or first dorsal interosseous; lower limb muscles such as quadriceps, hamstrings, tibialis anterior, soleus, and/or abductor hallucis muscles.
Only the authorized research team will use the device and the investigator will comply with USFDA requirements for monitoring, records and reports.
The research team will not market or promote the
|
Periprocedural
|
|
MVC
Periodo de tiempo: Periprocedural
|
Individuals will perform a maximum voluntary contraction (MVC) of the targeted muscles through surface electrodes secured to the skin over the belly of each muscle (Ag-AgCl, 10 mm diameter).
The signals will be amplified, filtered (20-1000 Hz), and sampled at 10 kHz for offline analysis.
|
Periprocedural
|
|
StartReact
Periodo de tiempo: Periprocedural
|
The StartReact response will allow us make inferences about the contribution of the reticulospinal tract to spasticity.
The StartReact response will be tested using a previously described paradigm in humans with and without SCI.
Here, participants will be asked to observe a light-emitting diode (LED) located ~1 m in front of the participants' head.
When the LED will illuminate (20 ms), individuals will be asked to perform an isometric elbow, knee and/or ankle flexion or an isometric elbow, knee and/or ankle extension as fast as possible.
We will measure the visual reaction time (VRT) as the time from cue to onset of the EMG burst in the elbow muscles after the LED presentation.
In some trials, the LED will be presented with either a quiet acoustic stimulus (80 dB, 500 Hz, 50 ms) or a startling acoustic stimulus (SAS, 120 dB, 500 Hz, 50 ms) delivered through a headphone.
The time delay between the presentation of the quiet acoustic stimulus and the onset of the EMG response refer as th
|
Periprocedural
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- STU00224061
- 1R01HD115345-01A1 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .